Clinical Trial Update: TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tumor-infiltrating lymphocyte–driven de-escalation of chemotherapy for Stage I-II triple-negative breast cancer; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: D'Or Institute for Research and Education | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING